Меропенем в терапии нозокомиальных пневмоний у взрослых пациентов


Белькова Ю.А., Зузова А.П., Козлов С.Н.

Проблема адекватной антимикробной терапии пациентов с нозокомиальной пневмонией (НП) сохраняет свою актуальность в связи с ростом резистентности микрофлоры, высокой летальностью и большими экономическими затратами. Меропенем является антибиотиком с широким антимикробным спектром, причем по сравнению с другими карбапенемами он характеризуется повышенной активностью в отношении грамотрицательных бактерий, в т. ч. устойчивых к другим антибактериальным препаратам. Это обусловливает его высокую значимость в терапии нозокомиальных инфекций различной локализации, включая НП и вентиляторассоциированную пневмонию. Хороший профиль безопасности меропенема позволяет рекомендовать его использование у тяжелого контингента больных в разных дозах и режимах введения.

Литература






  1. Santos SS, Machado FR, Kiffer CR, et al. Treatment of nosocomial pneumonia: an experience with meropenem. Braz J Infect Dis 2001;5(3): 124–29.

  2. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome ill. Clin Infect Dis 2000;31:131–38.

  3. Hoffken G, Niederman MS. Nosocomial pneumonia: the importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU. Chest 2002;122(6):2183–96.

  4. Kollef MH. Appropriate empiric antimicrobial therapy of nosocomial pneumonia: the role of the carbapenems. Respir Care 2004;49(12): 1530–41.

  5. Courvalin P. Evolutionary strategy of antibiotic resistance. Bull Mem Acad R Med Belg 2002;157(5–6):301–08.

  6. Hospital-acquired Pneumonia Guideline Committee of the American Thoracic Society & Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171(4):388–416.

  7. Руднов В.А. Вентиляторассоциированная пневмония: дискуссионные вопросы терминологии, диагностики и эмпирической антибиотикотерапии // КМАХ. 2001. № 3. С. 198–207.

  8. Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: risk factor for hospital mortality among critically ill patients. Chest 1999;115(2):462–74.

  9. Alvares-Lerma F. Modification of empiric treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med 1996; 22(5):387–94.

  10. Trouillet JL, Chastre J, Vuagnat A, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998;157(2):531–39.

  11. Jones RN, Mendes C, Turner PJ, et al. An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997–2004. Diagn Microbiol Infect Dis 2005;53:247–56.

  12. Страчунский Л.С. b-лактамазы расширенного спектра – быстро растущая и плохо осознаваемая угроза // КМАХ. 2005. № 1. С. 92–96.

  13. Wiseman LR, Wagstaff AJ, Brogden RN, et al. Meropenem: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1995;50(7):73–101.

  14. Edwards JR, Turner PJ. Laboratory date which differentiate meropenem and imipenem. Scand J Infect Dis 1995;(Suppl. 96):5–10.

  15. Hurst M, Lamb HM. Meropenem: a review of its use in patients in intensive care. Drugs 2000;59(3):653–80.

  16. Cornoglia G, Guan L, Fontana R, et al. Diffusion of meropenem and imipenem through the outer membrane of Escherichia coli K-12 and correlation with their antibacterial activities. Antimicrob Agents Chemother 1992;9:1902–08.

  17. Brown SD, Traczewski MM. Comparative in vitro antimicrobial activity of a new carbapenem, doripenem: tentative disc diffusion criteria and quality control. J Antimicrob Chemother 2005;55(6):944–49.

  18. Christensson ВA, Nilsson-Ehle I, Hutchison M, et al. Pharmacokinetics of meropenem in subiects with various degrees of renal impairment. Antimicrob Agents Chemother 1992;36(7):1532–37.

  19. Mattoes HM, Kuti JL, Drusano GL, et al. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin Ther 2004; 26(8):1187–98.

  20. Tomaselli F, Maier A, Matzi V, et al. Penetration of meropenem into pneumonic human lung tissue as measured by in vivo microdialysis. Antimicrob Agents Chemother 2004;48(6): 2228–32.

  21. Martindale: The complete drug reference. Sweetman SC (Ed) 33rd ed. London: Pharmaceutical Press, 2002:587.

  22. Edwards SJ, Emmas CE, Campb14ell HE. Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections. Curr Med Res Opin 2005;21(5): 785–94.

  23. Hou F, Li J, Wu G, et al. A randomized, controlled clinical trial on meropenem versus imipenem/cilaststin for the treatment of bacterial infections. Clin Med J (Engl) 2002;115(12):1849–54.

  24. Mouton YJ, Beuscart C. Empirical monotherapy with meropenem in serious bacterial infections. Meropenem Study Group. J Antimicrob Chemother 1995;36:145–56.

  25. Colardyn F, Faulkner KL. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group. J Antimicrob Chemother 1996;38(3): 523–37.

  26. Garau J, Blanquer J, Cobo L, et al. Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections. Eur J Clin Microbiol Infect Dis 1997;16(11):789–96.

  27. Sieger B, Berman SJ, Geckler RW, et al. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Meropenem Lower Respiratory Infection Group. Crit Care Med 1997;25(10):1663–70.

  28. Jaspers CA, Kieft H, Speelberg B, et al. Meropenem versus cefuroxime plus gentamicin for treatment of serious infections in elderly patients. Antimicrob Agents Chemother 1998;42(5): 1233–38.

  29. Verwaest C, Belgian Multicenter Study Group. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit. Clin Microbiol Infect 2000;6(6):294–302.

  30. Alvarez-Lerma F, Serious Infection Study Group. Efficacy of meropenem as monotherapy in the treatment of ventilator-associated pneumonia. J Chemother 2001;13(1):70–81.

  31. Яковлев С.В., Белобородов В.Б., Сидоренко С.В. и др. Анализ адекватности стартовых эмпирических режимов антибактериальной терапии при тяжелых нозокомиальных инфекциях (исследование АСЭТ) // Клиническая фармакология и терапия. 2006. № 2. С. 14–21.

  32. Norrby SR, Gildon KM. Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem. Scand J Infect Dis 1999; 31(1):3–10.

  33. Cunha BA. Meropenem in elderly and renally impaired patients. Int J Antimicrob Agents 1998;10(2):107–17.




Бионика Медиа